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SWI/SNF is a major regulator of gene expression. Its role is to facilitate the shifting and
exposure of DNA segments within the promoter and other key domains to transcription
factors and other essential cellular proteins. This complex interacts with a wide range of
proteins and does not function within a single, specific pathway; thus, it is involved in
a multitude of cellular processes, including DNA repair, differentiation, development, cell
adhesion, and growth control. Given SWI/SNF’s prominent role in these processes, many of
which are important for blocking cancer development, it is not surprising that the SWI/SNF
complex is targeted during cancer initiation and progression both by mutations and by
non-mutational mechanisms. Currently, the understanding of the types of alterations, their
frequency, and their impact on the SWI/SNF subunits is an area of intense research that
has been bolstered by a recent cadre of NextGen sequencing studies. These studies have
revealed mutations in SWI/SNF subunits, indicating that this complex is thus important for
cancer development.The purpose of this review is to put into perspective the role of muta-
tions versus other mechanisms in the silencing of SWI/SNF subunits, in particular, BRG1
and BRM. In addition, this review explores the recent development of synthetic lethality
and how it applies to this complex, as well as how BRM polymorphisms are becoming rec-
ognized as potential clinical biomarkers for cancer risk. Significance: Recent reviews have
detailed the occurrence of mutations in nearly all SWI/SNF subunits, which indicates that
this complex is an important target for cancer. However, when the frequency of mutations
in a given tumor type is compared to the frequency of subunit loss, it becomes clear that
other non-mutational mechanisms must play a role in the inactivation of SWI/SNF subunits.
Such data indicate that epigenetic mechanisms that are known to regulate BRM may also
be involved in the loss of expression of other SWI/SNF subunits. This is important since
epigenetically silenced genes are inducible, and thus, the reversal of the silencing of these
non-mutationally suppressed subunits may be a viable mode of targeted therapy.
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INTRODUCTION
SWI/SNF is a chromatin-remodeling complex first described in
the early 1990s. These studies showed that this complex opens
up the chromatin by shifting the position of histones and mak-
ing the DNA accessible to transcription factors and key cellular
proteins. In yeast, there is only a single complex, but in mammals
there are at least three different complexes. Each complex is com-
posed of one of two ATPase subunits, Brahma (BRM/SMARCA2)
or Brahma related gene 1 (BRG1/SMARCA4) and 8–10 other
subunits that results in a 2-MDa complex. In yeast, this com-
plex regulates about 5–6% of the genome, while in mammalian
organisms, it is not known how many genes are regulated by this
complex and how many protein interactions occur in conjunction
with this complex. However, SWI/SNF does not interact with one
type of transcription factor, but rather, it regulates the function
of many diverse genes as well as the function of many signaling
pathways. SWI/SNF has been found to function in DNA repair,
growth control, differentiation, development, cellular adhesion,
and immunity. In most cases, SWI/SNF functions in general to
maintain homeostasis and normal cellular function. The function
and composition of SWI/SNF is detailed in many other reviews
and is not the focus of this review. As SWI/SNF subunits are
frequently found to be mutated in different tumors, we com-
pared published mutation data (COSMIC and Atlas databases)
with published IHC (when available) to determine how frequently
mutations underlie the loss of expression of different SWI/SNF
units. As detailed below, in many cases, mutations cannot account
for why certain SWI/SNF subunits are silenced in cancer, which
suggests that other mechanisms likely underlie the loss of these
proteins in cancer.
DIFFERING ROLES FOR SWI/SNF IN CANCER, DEPENDING ON
THE CONTEXT
SWI/SNF functions as an epigenetic regulator that opens and
closes the chromatin, thereby helping to turn gene expression on
and off. In this capacity, the complex serves as both an onco-
gene and a tumor suppressor, depending on the protein with
which it is interacting (1). Abrogation of SWI/SNF can impact the
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normal functions of DNA repair, cellular differentiation, devel-
opment, and cell adhesion (2). Its diversity in function has been
recently demonstrated by contrasting sets of publications about
the role of one of its two catalytic subunits, Brahma (BRM, or
SMARCA2), in cancer. Traditionally, BRM has been viewed as a
tumor susceptibility or tumor suppressor protein because its loss
can potentiate the development of tumors in murine cancer mod-
els (3, 4) as well as portend worse clinical survival in lung cancer
patients (5, 6). In addition, BRM loss in non-transformed cell
lines has been shown to prevent cells from entering a canonical
quiescent state (7), which further attests to the growth-inhibitory
functions ascribed to BRM. Several labs have shown that BRM
is necessary for RB function (8–10): it is known to bind to RB
(11), and together, RB and BRM suppress the activity of E2F (12).
A constitutively active form of RB fails to inhibit growth when
introduced into BRM-deficient cell lines, as well as in cells that
are deficient in its homolog, Brahma-related gene 1 (BRG1, or
SMARCA4), which is the second catalytic subunit of SWI/SNF
(10). In fact, re-expression of BRM can inhibit growth and induces
differentiation in a variety of BRG1/BRM-deficient cell lines (8), a
process that is disrupted by viral proteins that bind to RB, such as
E1A or E7 (8, 13). Moreover, BRM re-expression has been shown
to antagonize KRAS-transformed cells by partially reversing the
transformed phenotype and substantially slowing growth; based
on these data, these authors concluded that increased BRM expres-
sion promotes the entry of cells into G1/G0, while the loss of BRM
expression may foster oncogenic transformation (14). BRM has
been shown to promote exit from the cell cycle and cell differen-
tiation in retinal ganglion cells (15). Re-activation of BRM and
SWI/SNF appear to foster the active, hypophosphorylated form
of RB through the inhibition of cyclin D1 by directly binding to
its promoter and stimulating the downregulation of cyclin D1 as
well as the induction of p16 (16, 17). Thus, numerous studies have
clearly defined a growth-inhibitory role for BRM and SWI/SNF.
Apparently contrasting sets of observations, however, suggest a
dichotomous function for BRM. These findings imply that BRM
and SWI/SNF may not solely function in growth-inhibitory path-
ways but may also serve in a net stimulatory capacity. Thus, the
function of BRM depends on the context. This concept has been
directly observed in BRG1-deficient cell lines where the knock-
down of BRM actually slows growth. This has been described as
synthetic lethality – a term, which describes the situation where the
loss of function of two or more genes leads to cell death, but where
the loss of function in only one of the genes is not lethal. This
finding of synthetic lethality after BRM knockdown has also been
found to occur in xenograft models (18–20). These data indicate
that BRM is necessary for stimulatory pathways – or, alternatively,
that BRM may act as an antagonist to growth-inhibitory path-
ways (i.e., it acts as a dominant negative). Potentially important
to these observations is the fact that BRM has been shown to
be regulated post-translationally, where the acetylation of BRM
blocks BRM-dependent gene expression (16) and conversely, the
removal of BRM acetylation causes growth arrest (16). In at least
a subset of the cell lines used to demonstrate synthetic lethality,
BRM is actually known to be acetylated, which suggests that its
growth-inhibitory functions are likely turned off (unpublished
observations) (16, 21).
In this particular context, which in this case is in BRG1-deficient
genotypes, experimental silencing of BRM has been observed to
significantly slow cancer cell growth rather than promote it (19).
At least two rationales might explain this observed phenomenon.
First, if BRM and SWI/SNF function in the growth-promoting
pathway, then their suppression would diminish their respec-
tive contributions to this pathway and would likely cause slower
growth, as observed. To this end, SWI/SNF and BRM have been
shown to be cofactors for such oncogenes as C-Jun and C-Myc
(22, 23). Second, at least a subset of the cells that have demon-
strated synthetic lethality harbor a form of BRM that is acetylated
at the C-terminus (16), which means that BRM is likely inacti-
vated in these cell lines (21). The frequency of BRM acetylation
in primary tumors is not yet known, but BRM acetylation is esti-
mated to occur in 65–70% of cancer cell lines, which suggests that
BRM acetylation also occurs frequently in primary tumors (21).
We have shown that the deacetylation of BRM promptly induces
growth arrest (21). In this capacity, BRM may be functioning as
a dominant negative, much like p53 does when mutated. Alter-
natively, the role of BRM may be dictated by its acetylation state,
where its unacetylated form binds to RB and RB2 and enhances
growth inhibition, and its acetylated form antagonizes RB and
also functions in growth pathways such as those driven by onco-
genes (e.g., C-Myc and C-Jun). We favor the latter hypothesis, as it
explains the majority of experimental observations and minimizes
the apparent contradictions in the data, for example, where BRM
re-expression as well as BRM knockout can both result in growth
inhibition in certain cellular contexts, as outlined in our recent
Cancer Research editorial (24). In addition, there are at least three
different acetylation sites. Whether each acetylation site governs
a different activity of BRM or all three are required to inactivate
BRM is not yet known. Nevertheless, these new data demonstrate
that BRM, BRG1, and SWI/SNF have potentially different roles
depending on the context.
SYNTHETIC LETHALITY AND THE CLINICAL SILENCING OF
BRM
Based on the observation that the knockdown of BRM in BRG1-
deficient cell lines induces synthetic lethality, the clinical silencing
of BRM has been suggested as a therapeutic strategy. Yet, this
approach may not take into account the other anti-cancer func-
tions of BRM and SWI/SNF. SWI/SNF and BRM are known to
regulate cellular adhesion, DNA repair, differentiation, and expres-
sion of MHC class 1 and 2 proteins (2). Hence, while their suppres-
sion in certain circumstances might promote growth inhibition,
it is equally possible such a strategy could have adverse clinical
consequences by accelerating de-differentiation and promoting
metastasis by inhibiting the expression of adhesion proteins such
as E-cadherin, CEACAM1, integrins, and CD44, which are known
to be regulated by SWI/SNF (2, 25). Moreover, the loss of both
BRG1 and BRM would favor the inhibition of DNA repair (2, 25),
and in particular, such key DNA repair genes as GADD45 (26),
which in turn could enhance tumor progression. As SWI/SNF
is reported to regulate MHC class 1 and 2 proteins (27–29), the
silencing of BRM might result in the loss of these proteins, impair-
ing the normal function of the immune system (30). BRM and
the SWI/SNF complex have roles in the maintenance of genomic
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integrity and are required for the correct segregation of chromatids
(7). BRM loss might also impact gene expression by changing the
splicing pattern of genes such as CD44, Cyclin D1, and BIM (31).
There are many positive functions governed by SWI/SNF that are
yet to be well defined, and they might also be compromised if BRM
is clinically silenced.
It might be a better approach to understand the mechanism
that underlies synthetic lethality in this context before pursuing
it as a mode of clinical therapy. For example, if BRM acetylation
is truly a component of this phenomenon, the reversal of acetyla-
tion might be a prudent and feasible approach to affect the growth
control function of BRM as well as the restoration of BRM’s other
anti-cancer functions. This is because deacetylation in vitro results
in growth inhibition and in the restoration of the transcriptional
ability of BRM (16, 21). To this end, we know that BRM acetyla-
tion is governed by the functional balance of at least three proteins:
HDAC2, KAT2B, and KAT8 (21). It is possible that aberrant KAT
activity could be driving the acetylation of BRM in cancer, as KATs
are known in certain cancer types to be hyperactive due to overex-
pression and the formation of hybrid/fusion proteins (32–34). In
particular, as synthetic lethality has been observed in lung cancer-
derived cell lines, it is interesting to note that KAT2B (GCN5,
PCAF) is overexpressed in lung cancer – and this same protein
has been shown to drive the expression of the cell cycle genes
E2F1, cyclin D1, and cyclin E1 (35). The targeting and inhibition
of KAT2B also inhibit cancer by a variety of mechanisms (36–38),
besides restoring BRM function. Hence, it may be more clini-
cally appropriate to restore BRM function and its ability to inhibit
growth by simply targeting KAT2B activity, rather than to silence
BRM and risk the loss of BRM’s other anti-cancer functions. Fur-
ther studies into the mechanism of BRM synthetic lethality and
acetylation are needed to complete this complex picture before the
best clinical avenues can be pursued.
THE RB PATHWAY AND SWI/SNF
The SWI/SNF complex has been implicated in the function of the
RB pathway ever since it was identified in mammalian cells. In two
papers published in the mid-1990s (8, 39), Dr. Goff ’s research
group was one of the first to show this functional interaction
between SWI/SNF and RB. They first demonstrated the interac-
tion with a yeast two-hybrid system and showed that RB bound
specifically to BRG1 and BRM and that the RB-dependent growth
inhibition was dependent on the binding of RB to these SWI/SNF
subunits (39). Next, they showed that the re-introduction of BRG1
or BRM caused growth inhibition that was dependent on members
of the RB family, including RB, RB2 (p130), and to a lesser degree,
p107 (8). This clearly established the functional interaction and
RB dependence on the SWI/SNF complex. Several labs thereafter
demonstrated that the growth inhibition induced by the ectopic
expression of p16 or by the constitutively active isoform of RB
required a functional SWI/SNF complex (9, 10, 40–42). Specif-
ically, neither transduction with p16 nor transient transfection
with RB could effectively induce growth arrest in BRG1/BRM-
deficient cell lines (e.g., SW13, C33A, H522, etc.); at the same
time, the re-expression of either BRG1 or BRM in conjunction
with the re-expression of either p16 or constitutively active RB
were both sufficient to restore RB-dependent growth inhibition.
Interestingly, growth inhibition can also occur in the absence of RB
in cell lines such as C33A and Saos-2, which harbor a functional
p130 protein (43, 44). This is important because unlike RB, p130 is
rarely mutated in cancer and retains its function in the control of
the G1 to G0 transition, which is necessary for cancer stem cells to
become quiescent (45). This fact coupled with the need for p130
to bind and cooperate with SWI/SNF might explain why BRG1
and BRM are not frequently mutated. The epigenetic regulation
of BRG1 and BRM would allow cancer cells to become quiescent
and thereby escape the cytotoxicity of standard chemotherapy as
well as maintain their ability to subsequently re-enter the cell cycle.
This mechanism could also allow cancer cells to delay re-entry into
the cell cycle, which could explain why cancers can recur at various
times after their initial discovery and treatment.
Interestingly, in most reviews and papers, SWI/SNF inacti-
vation is infrequently considered as an alternative method of
inactivating the RB pathway. Since the loss of BRG1, BRM, or
both is commonly observed in many cancer types, the disruption
of the RB pathway likely occurs from a loss of SWI/SNF activity
in a subset of tumors (6, 19). Post-translational modifications via
phosphorylation are also known to occur in both BRG1 and BRM
(46). These modifications shift these proteins from the nucleus to
the cytoplasm as cells enter M-phase, but this process is reversed
when cells enter G1 phase (46). Whether cancer can highjack this
regulatory mechanism as a means to inactivate either protein is
not currently known. Some tumors, however, do display promi-
nent cytoplasmic staining, which suggests that BRG1 or BRM must
translocate to the cytoplasm (3, 5, 6). Further research is required
to determine the scope of these epigenetic mechanisms and their
implications for cancer development, progression, and recurrence.
BRM SILENCING AND BRM POLYMORPHISMS
The role of BRM in cancer initially appeared to be different from
that of BRG1. In particular, a BRM knockout in animal models
generates a phenotype that does not precipitate cancer de novo, but
rather acts synergistically with carcinogens to yield tumors (3, 47).
Hence, BRM loss would appear to foster cancer development when
partnered with other changes such as exposure to carcinogens,
rather than produce cancer by itself akin to driver oncogenes (48).
In the pursuit to determine how BRM is silenced, it was found
that in cell lines, BRM is epigenetically silenced, and its expres-
sion can be pharmacologically restored (49). It has since been
found that the loss of BRM expression can be robustly reversed
by flavonoids in general, and more specifically, by the synthetic
flavonoid flavopiridol (50), which is now being tested in clini-
cal trials (51). Recently, flavopiridol has been shown to inhibit
the growth of rhabdoid tumors, which are deficient in BAF47
(SMARCB1; INI1) and commonly deficient in BRM as well (52).
The induction of BRM is likely important to the growth-inhibitory
mechanism of flavopiridol, as BRM silencing blunts flavopiridol-
mediated growth inhibition in rhabdoid cell lines as well as in
other cancer cell lines (50, 52). Interestingly, in addition to the
ability of flavonoids to induce BRM in BRM-deficient rhabdoid
tumor cell lines, the re-expression of BAF47 was also observed to
have the modest effect on the restoration of BRM (52), indicating
the existence of a cross-regulatory mechanism between SWI/SNF
subunits. The re-expression of BAF47 has no effect, however, on
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HDAC9 or GATA3 expression, which are tightly linked with BRM
silencing in cancer cell lines and primary tumors (21, 52). These
data suggest that the restoration of BRM could be a mode of tar-
geted therapy, since specific compounds (such as flavopiridol) are
available that could be used, in theory, to inhibit cancer growth
when applied to BRM-deficient cancers. The use of small mole-
cule inhibitors or antibodies to block or inhibit aberrant activating
kinases has become a standard clinical approach for the treatment
of cancers. Yet, cancer is not only driven by aberrantly functioning
gas pedals (oncogenes) but it also evolves as a result of the loss of
brakes (tumor suppressors). Hence, the reversal of BRM silencing
is another illustration of how an epigenetic mechanism can be
reversed as a means for targeted therapy.
In order to successfully apply targeted therapies, ideally one
should have biomarkers to identify those patients who would
most likely benefit from a given therapy. To this end, during the
pursuit to determine how BRM was silenced, we discovered two
germline insertional polymorphisms within the BRM promoter
(53). Both of these polymorphisms lie upstream of the transcrip-
tion start sites within the first ~1300bp of the BRM promoter.
The −741 polymorphic site is a triplicate repeat of the sequence
TATTTTT, while the wild-type genotype is a duplicate repeat of
this sequence (Figure 1). Similarly, the −1321 polymorphic site
is a duplicate of the sequence TTTTAA, whereas the wild-type
sequence contains this sequence only once (Figure 1) (53). Upon
the discovery of these polymorphisms, two characteristics were
readily observed. First, these two insertional polymorphisms have
a remarkably high homology with MEF2 binding sites (54). In
Caucasians, each of these polymorphisms is in Hardy–Weinberg
equilibrium and occurs at a frequency of ~20% individually, while
the frequency of the combined polymorphisms is roughly 6%.
Second, the presence of either one or both polymorphisms statis-
tically correlated with the loss of BRM expression in cancer cell
lines (53). This statistical correlation was also found to be true in
primary lung cancers (53). These polymorphisms would appear to
be good surrogate biomarkers for BRM silencing in cancer given
their strong correlation with BRM loss.
FIGURE 1 | BRM promoter polymorphisms. The two insertion
polymorphisms located in the promoter of the BRM gene are illustrated
here. The −1321 polymorphic site (poly 1321) (rs3832613 or rs5925917) is
located 1321 bp upstream of the transcription start site and contains an
additional 6 bp insertion, TTTTAA, to yield a duplicate repeated sequence
“TTTTAA-TTTTAA,” while the wild-type allele only has a single “TTTTAA”
sequence present. The −741 polymorphic site (poly 741) (rs34480940) is
located 741 bp from the transcription start site and contains an additional
7 bp insertion, TATTTTT, to yield a triplicate “TATTTTT-TATTTTT-TATTTTT”
sequence, while the wild-type sequence consists of the duplicate
sequence “TATTTTT-TATTTTT”.
MECHANISM OF THE EPIGENETIC SILENCING OF BRM
As these polymorphisms were observed to be more prevalent in
cancer cells that lack BRM expression, this suggested that they
could be involved in BRM silencing. The high homology of
these polymorphic sites with a known MEF2 binding site indi-
cates that one of the MEF2 family members may be involved in
BRM silencing. MEF2 transcription factors are known to silence
genes by the recruitment of histone deacetylases (HDACs) (55,
56), and pan-HDAC inhibitors robustly restore BRM expression
(57). Unfortunately, these pan-HDAC inhibitors also cause BRM
acetylation and the subsequent inactivation of BRM. As such, these
compounds cannot be practically used to restore BRM expression
(16). This observation, however, indicated that HDACs must at
least partially underlie BRM silencing. To this end, the shRNA-
mediated knockdown of HDAC3 and HDAC9 robustly induced
BRM, thereby showing that these specific HDACs are directly
involved in BRM silencing (21). Similarly, the knockdown of both
MEF2D and GATA3 also induced BRM, implying that these tran-
scription factors are also part of the BRM silencing mechanism.
While none of these proteins was found to be mutated in BRM-
deficient cancer cell lines, HDAC9 and GATA3 were overexpressed
in both lung cancer-derived cell lines and primary lung tumors, as
well as in rhabdoid cell lines and primary tumors (21, 52). GATA3
and MEF2D,moreover, are known to bind to the HDAC9 promoter
and drive HDAC9 overexpression (58). Just why HDAC9 over-
expression appears to selectively occur in BRM-deficient cancer
cells is not known. As HDACs are counter balanced by the activ-
ity of lysine acetyltransferases (KATs), it is not surprising that in
BRM-deficient cell lines, ectopic expression of KAT6A, 6B, and/or
7 also induces BRM (21). Although KATs are often mutated or
rearranged to form hybrid fusion proteins in many cancer types
(32, 59), no alterations or mutations were observed in KAT6A, 6B,
or 7 in BRM-deficient cancer cell lines (21).
Screening BRM-deficient cell lines with a library of kinase
inhibitors led to the finding that the MAP kinase pathway also
regulates BRM upstream of HDAC9 and GATA3 (52). Why an
activated MAPK pathway leads to BRM silencing in only some cir-
cumstances is not known but appears to be linked to the presence
of the BRM polymorphisms. The involvement of BRM polymor-
phisms has been further connected to BRM silencing by ChIP
experiments showing that HDAC9 and MEF2D bind to the BRM
promoter only when the BRM polymorphisms are present (52).
Interestingly, MEF2D recruits HDAC9 to promoter regions, where
it silences specific genes (56, 60). Hence, it appears that the activa-
tion of the MAP kinase pathway activates MEF2D, which in turn
recruits HDAC9 to the BRM promoter by binding to the BRM
polymorphisms. We surmise that this then leads to the removal of
acetylated chromatin marks, such as H3K9 and H3K14 that con-
trol gene expression. The removal of these chromatin marks then
prompts the closure of the chromatin and silencing of the BRM
gene. Based on these data, the clinical targeting of BRM could be
accomplished by inhibition of the MAP kinase pathway via FDA-
approved inhibitors of B-raf such as vemurafenib and dabrafenib.
Alternatively, as HDAC9 is a class 2 HDAC, its expression is rel-
atively tissue-specific, and because it is highly overexpressed in
BRM-deficient cancer cells, it might be a viable target for therapy. It
is important to note that whileBRM is silenced by this mechanism,
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it is unlikely that BRM is the only gene regulated by this aberrant
gene silencing mechanism. Thus, targeting this mechanism may
have broad anti-cancer effects, unrelated to BRM.
BRM POLYMORPHISMS, CANCER RISK AND CLINICAL
OUTCOME
While the loss of BRM per se does not independently drive cancer
development in mice, BRM loss appears to tip the balance toward
cancer development. The data from murine models indicate that
BRM is not a tumor suppressor gene like RB or p53, but rather
that it can function as a tumor susceptibility gene (3). Since the
BRM polymorphisms appear to be surrogate markers for BRM
loss (53), we surmised that these polymorphisms would correlate
with cancer development. To investigate this possibility, a series of
case control studies was undertaken, and each showed a statistical
correlation with lung cancer risk with odds ratios between two and
three (53, 61, 62). BRM polymorphisms have not only predicted
lung cancer in repeated studies, but these markers also appear to
be predictive of the cancer risk for other tumor types, including
head/neck cancer (63). Loss of BRM protein expression in primary
lung tumors has also been associated with a worse clinical outcome
in patients (5, 6). BRM polymorphisms also have a statistical cor-
relation with a worse outcome in patients with liver cancer (64).
Based on these data, the BRM polymorphisms are emerging as
predictive biomarkers in a variety of tumor types. Given the link
between the BRM polymorphisms and BRM expression, it may be
feasible to reverse the predictive trends of this biomarker by the
induction of BRM or by the prevention of BRM silencing. To this
end, flavonoids (42/42) from each of the six structural groups were
observed to readily induce BRM, which suggests that BRM might
play a part in the anti-cancer properties of flavonoids (50). It is
intriguing to speculate that the role of BRM silencing in cancer risk
and cancer development could be counter balanced by the dietary
consumption of flavonoids, which readily restore BRM and foster
the activation of RB (50).
MUTATIONS IN SWI/SNF SUBUNITS
SinceBRM is reversibly epigenetically silenced in cell lines, it could
be considered a target for therapy in tumors. For such therapies
to be developed, however, it must be proven that BRM is not fre-
quently silenced by mutations. As this axiom holds true for other
SWI/SNF subunits, it is informative to determine the rate of a par-
ticular subunit’s mutation frequency versus its frequency of loss
in a given tumor type. Mutations within the different SWI/SNF
subunits have been well documented and described by a number
of important reviews (65, 66). To ascertain the relative impor-
tance and role of each mechanism, it is useful to compare the
frequency of mutations to other forms of gene alterations and
inactivation. Four major sources have recently been mined to
reveal such information about SWI/SNF: The Cancer Genome
Atlas (TCGA) database, the Catalog of Somatic Mutation in Cancer
(Cosmic) database, Sanger Sequencing publications, and available
IHC data. In this review, we will focus on the comparison of the
data in the Atlas database with published IHC data, and when
possible, we will include mutation data from the Cosmic data-
base. The Cosmic data will be denoted by percentage of mutations
enclosed by brackets “(%)” and the TCGA data will be denoted
by percentage of mutations enclosed by parentheses “(%).” In dis-
cussing mutations, it is prudent to acknowledge that mutations
that change a single amino acid residue via missense might have a
functional consequence, but this is not always easy to determine,
and in most cases, functional data that explore the variable impact
of such mutations are lacking. In contrast, gene alterations such
as aberrant splicing, nonsense mutations (stop codons), or indels
(frame shifts), which block the expression of a SWI/SNF sub-
unit or result in the expression of a truncated protein, would be
expected to have a much greater impact on the overall function of
the mutated subunit, the SWI/SNF complex, and the pathways that
are functionally dependent on this complex. NextGen sequencing
studies have revealed a gamut of missense mutations that impact
an unknown percentage of cancer cells within tumors, as sum-
marized in a recent review (65). In general, current sequence
data have not yet demonstrated specific hotspots in SWI/SNF
subunits, making mutational analyses harder to interpret. More-
over, specific mutations or deletions in certain regions may fail to
abrogate protein function. For example, the C-terminal trunca-
tion that causes the loss of the bromodomain of BRG1 has been
reported to not block its ability to cooperate with RB and inhibit
growth (10).
OTHER CONSIDERATIONS IN THE SILENCING OF BRG1
AND BRM
While it is frequently assumed that abrogating mutations such
as indels and nonsense mutations (and probably missense muta-
tions) are ubiquitous and homogeneous throughout tumors,
immunohistochemical staining of tumors for BRG1 and BRM has
shown that loss of expression has a variable penetrance in a given
tumor (6). Such staining can vary by gene expression intensity
and/or by the pattern of gene expression loss from a uniform to a
mosaic or intermittent pattern as seen in Figure 2. In the absence
of complete and homogeneous loss of gene expression, the impact
of these other modes of gene expression alterations will invariably
impact SWI/SNF and cancer to varying degrees. To complicate
this matter, since SWI/SNF is a chromatin-remodeling complex,
and thus a catalyst for opening and closing DNA to modulate gene
expression, the level of expression of its subunits may not have
a linear impact as is seen with other genes. Rather, there may be
threshold effects where, despite a lower level of expression of a
given subunit, SWI/SNF may have relatively preserved levels of
function, and only when the subunit levels drop below a critical
level does the SWI/SNF complex become functionally impaired.
To this end, lower levels of BRG1 and BRM have been frequently
observed in different tumor types (6). Therefore, the sub-threshold
levels of a given subunit could be another mechanism by which
SWI/SNF function might be perturbed. In support of this assertion
is the observation that heterozygous loss of BRG1 and BAF47 pre-
dispose mice to tumor development (67–71). As many mutations
in SWI/SNF subunits are missense, it is not known if these mis-
sense mutations function as dominant negatives or simply impair
or abrogate function, causing a relative state of haploinsufficiency.
In the setting where a given mutation (e.g., indel or nonsense)
causes a loss of function of a given SWI/SNF subunit, these muta-
tions usually only occur in one of the two alleles. The impact of
the mutated allele depends in part on the status of the other allele.
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FIGURE 2 | Mosaic pattern of BRG1 expression in human tumors. An
ovarian (A) and liver (B) tumor both show an overtly mosaic pattern of BRG1
staining activity. BRG1-positive cells (brown) are observed adjacent to
BRG1-negative cells (blue). This demonstrates the heterogeneous nature of
these tumors with respect to loss of expression of the SWI/SNF subunits, in
this case, BRG1. These pictures illustrate the problems in deciding whether a
tumor is actually negative for expression of a given subunit. Original
magnification: 63x; scale bar=20µm.
Such abrogating mutations in SWI/SNF subunits could have an
impact, for example, if haploinsufficiency in a given subunit por-
tends cancer development. A single allelic loss of BAF47 or BRG1
has been shown to promote a low but discernible rate of tumor
formation in mice (71). Since excess SWI/SNF subunits are gen-
erally degraded (72), the protein expression from one allele could
generate the required number of functional SWI/SNF complexes
to avoid cancer development. If true, this mechanism could dimin-
ish the impact of allelic loss of a given subunit on the function of
the complex and thus be considered a safeguard against transfor-
mation. However, when abrogating mutations (e.g., in ARID1A,
ARID1B, and PBRM1) occur, they are frequently accompanied by
loss of heterozygosity, leading to the complete loss of expression
(see section below).
Another important consideration is the possibility of the func-
tional redundancy of subunits, in particular BRM and BRG1,
which are catalytic homologs within SWI/SNF (73, 74). While
certain studies distinguish a functional difference between BRG1-
and BRM-containing complexes, including differential interac-
tions with specific transcription factors (75), other studies indicate
that these subunits and their respective complexes can also substi-
tute for one another if one subunit is suppressed or inactivated (2).
This is most apparent in the studies of RB-mediated growth inhi-
bition, where both BRG1 and BRM were shown to equally interact
with RB and foster RB-mediated growth inhibition (8–10, 39).
Given these findings, it is not surprising that in some tumors, such
as lung cancer, the concomitant loss of BRG1 and BRM occurs in
a significant portion (8–10%), compared with the loss of expres-
sion of either subunit alone, which occurs in 20–30% (5, 6, 76).
Clearly, based on in vitro experiments, the value of inactivating
both subunits eliminates any possibility of complementation and
residual functionality of the SWI/SNF complex, in comparison
with the silencing of either BRG1 or BRM alone. In addition to
BRG1 and BRM, functional redundancy may exist among other
subunits (e.g., BAF60A, BAF60B, and BAF60C; or BAF155 and
BAF170; or ARID1A and ARID1B), which suggests a mechanism
by which the SWI/SNF complex may be further protected from
cancer-driven subunit loss (2, 25).
LOSS OF HETEROZYGOSITY AND THE SWI/SNF SUBUNITS
The BRG1 locus is known to be an area of loss of heterozygos-
ity and lies adjacent to LKB1 at 19q13.3 (77, 78). Similarly, the
BRM locus is distal to p16 on the short arm of chromosome 9 at
9p23–24, which is another area of loss of heterozygosity (79–81).
Both the BRG1 and BRM loci are therefore areas where loss of het-
erozygosity is known to occur in primary tumors (2, 82). In many
cell lines that lack BRG1 or BRM, one allele has been lost (unpub-
lished data).ARID1A lies at 1q25.3, which is another area of loss of
heterozygosity (83, 84). Interestingly, ARID1B is located at 6q25,
an area of known loss of heterozygosity that has been linked to a
documented genomic loss that drives inherited diseases of intel-
lectual disability as well as multiple spinal meningiomas (85, 86).
Moreover, the 6q25 locus is one of several regions that is frequently
lost in central nervous system tumors, particularly in childhood
neuroblastoma (87), where ARID1B and ARID1A are involved in
11% of these cases (88). ARID2 maps to 12q12, an area that dri-
ves adenoid cystic carcinoma (89). PBRM1 (BAF180) is located at
3p21.1, which is frequently lost in a variety of tumors (90). While
3p21 is frequently lost in lung cancer (91), PBRM1 does not seem
to be targeted in this cancer (92). In contrast, PBRM1 involve-
ment in 3p21 loss of heterozygosity in renal cell carcinoma is well
documented and correlates with frequent mutations in PBRM1 in
this tumor (93). While loss of heterozygosity is frequently coupled
to mutations that result in the inactivation of a target gene, loss
of heterozygosity can also be coupled to epigenetic silencing. For
example, most if not all BRM-deficient cell lines exhibit loss of
heterozygosity (3, 52). Together, these observations regarding the
loss of heterozygosity suggest that these genes can be more easily
silenced when either mutational or non-mutational mechanisms
occur in the remaining allele.
IDENTIFICATION OF BRG1 MUTATIONS IN CELL LINES
VERSUS A LACK OF MUTATIONS IN PRIMARY TUMORS
Defining BRG1-inactivating mechanisms in primary tumors has
been hampered because of the initial discovery of BRG1 muta-
tions in cell lines (94, 95). A number of groups have sequenced
BRG1 in both BRG1-positive and BRG1-negative cell lines, and
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both missense and abrogating mutations have been reported in
the vast majority of BRG1-deficient cell lines. In a minority of
BRG1-deficient cell lines, such as C33A, H1573, and Panc-1, no
detectible mutations have been found (unpublished data) (94).
Interestingly, qPCR experiments by our lab have revealed that the
levels of BRG1 mRNA in cell lines are much lower if BRG1 is
silenced by mutations compared to BRG1-deficient cell lines that
lack mutations. We have also found that BRG1 is inducible in those
cell lines that lack definable mutations (52). These findings give
credence to the possibility that BRG1 is epigenetically regulated in
a subset of cancer cells. At least in cell lines, qPCR could serve as a
preliminary screening mechanism to determine how BRG1 might
be silenced.
Some reports have implied that becauseBRG1 is mutated in cell
lines, it must also be mutated to the same degree in primary tumors
(95), and BRG1 has been shown to be silenced by mutations
in >65–70% of human cancer cell lines in a number of studies
(94–96). These cell line data have driven speculation that muta-
tions must be the primary mechanisms by which cancer targets
and inactivates BRG1. Yet, the data from the NIH Atlas database
demonstrate that the average weighted frequency (Table 1) and the
average unweighted (Table 2A) frequency of abrogating mutations
for BRG1 in 23 [13] human tumor types is 0.4 and 0.21%, respec-
tively, out of a total mutation rate of 3.75% (unweighted) and
2.41% (weighted)-which is well below the rate of BRG1 silencing
found in many human tumors (15–30%) according to published
IHC data (5, 97). For example, according to the Atlas database, the
rates of total mutations for BRG1 in melanoma, pancreatic cancer,
and head/neck cancer are 7.83, 7.69, and 5.88%, respectively, but
the rate of abrogating mutations is <0.3, 1.1, and 0.33%, respec-
tively (Table 2A); in comparison, the loss of BRG1 by IHC in these
two tumors is far higher, ~10–27, ~10–25, and ~18%, respectively
(98–100) (Marquez et.al. submitted Oncotarget 2015). Similarly,
the rate of abrogating mutations of BRG1 in colon and breast can-
cers is (0.0%) [1.28%] and (0.71%) [0.39%], respectively, while
BRG1 is silenced in >25% of these cancers as determined by IHC
(Table 2A). In fact, the weighted average of abrogating and non-
abrogating mutations as well as the total mutation rate for BRG1
from the Atlas database from 23 tumor types is 0.21, 2.20, and
2.41%, respectively (Table 1). The data from the Atlas database
are consistent with Sanger sequencing studies of BRG1 in lung
cancer, where abrogating BRG1 mutations (squamous and adeno-
carcinoma) are relatively low at 0.56 and 3.31% of tumors, while
the loss of BRG1 expression occurred in ~15–30% (6, 19, 76, 101).
Moreover, no abrogating mutations in BRM have been found in
lung cancer. BRM is not significantly mutated (0.0%) as indicated
by the Atlas data, which is clearly below the frequency at which its
expression is lost in lung cancer (3, 5, 19).
A weighted frequency by cancer incidence shows that all muta-
tions in SWI/SNF subunits occur in ~16% of these 23 human
tumor types, where 15.5% of those tumors that harbor SWI/SNF
mutations have more than one mutation. In comparison, the
mutation rate of SWI/SNF subunits was reported as 20% in a
recent review, which reported an unweighted average based on the
number of tumors analyzed (65), rather than on the incidence
and/or prevalence of these cancers; the latter more accurately
reflects their true frequency in a population of cancer patients.
Table 1 |Weighted averaged mutations of SWI/SNF subunits.
Total Total Total (%)
Abr (%) Non-Abr (%)
SMARCD1 0.05 0.22 0.27
SMARCE1 0.10 0.27 0.40
SMARCD2 0.04 0.57 0.64
SMARCB1 0.13 0.43 0.66
SMARCD3 0.07 0.67 0.88
SMARCC1 0.06 0.91 0.97
SMARCC2 0.33 1.02 1.45
PBRM1 0.55 1.25 1.69
SMARCA2 0.09 1.84 1.96
SMARCA4 0.21 2.20 2.41
ARID1B 0.50 2.32 3.05
ARID2 1.68 2.40 4.24
ARID1A 2.55 2.16 4.83
Total 6.34 16.18 23.72
Adjusted total 5.19 10.30 15.49
This table gives the percent abrogating, non-abrogating, and total mutations in
each of the 23 tumor types for each SWI/SNF subunit shown. For each tumor
type listed, the reported number of silent, missense, nonsense, and indel muta-
tions as well as the number of deletions and splicing defects for each SWI/SNF
gene were tabulated. Then, the total number of abrogating mutations (non-
sense+ indels+deletion+ splicing defects) and the number of non-abrogating
mutations (missense+ silent) were calculated.The frequency for each cancer was
calculated by recording the number of new cases for each of these 23 tumors
then dividing by the number of total new cancer cases in United States. The
weighted frequency was calculated by multiplying the frequency of abrogating,
non-abrogating, and total mutations for each SWI/SNF subunit by the cancer fre-
quency for each tumor type (Table S2 in Supplementary Material). The weighted
mutation frequency for each SWI/SNF subunit was then calculated by summing
the products of the frequency (cancer frequency times the mutation frequency)
for each of the 23 cancer types. The adjusted total mutation frequency is the
number of tumors with at least one SWI/SNF subunit mutation divided by the
total tumor analyzed.
In comparison, the mutational data on BRM in cell lines are
consistent with experimental observed mutation rates in pri-
mary tumors; we did not observe any BRM mutations after we
sequenced 20 primary lung cancers (3). Indeed, few if any cell line
studies have shown that BRM is silenced by mechanisms other
than epigenetic ones (3). These findings have been supported
by the low levels of abrogating mutation rates (0.10%) [0.08%]
detected when BRM has been sequenced in primary tumors,
according to the Atlas database (Cosmic database) (Table 2B).
This fact is critically important, as it shows that other mechanisms
are at play that inactivate and silence BRM, and likely BRG1, in
lung cancer. Given the available IHC data for BRM and BRG1 in
other cancers, this observation also appears to be true in other
cancer types, and similarly, other mechanisms likely underlie how
BRM and BRG1 are silenced in a variety of cancers.
OTHER MECHANISMS THAT SILENCE BRG1?
A comparison of IHC data with NextGen sequencing data clearly
shows that non-mutational mechanisms must also underlie most
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of the BRG1 silencing in at least a subset of human cancers.
Even before NextGen sequencing became a major experimen-
tal technique, Sanger sequencing in BRG1-negative tumors (as
defined by IHC) showed that the frequency of abrogating muta-
tions likely occurred in only a minority of these BRG1-negative
tumors. For example, Oike et al. sequenced 16 BRG1-deficient
lung cancers for BRG1 mutations and found only one tumor
with molecular alterations (missense mutation) (19). A limited
analysis of gastric tumors also demonstrated a lack of BRG1
mutations (112). Rodriguez-Nieto et al. analyzed 122 tumors,
of which 46 (37%) were found to have low to null levels of
BRG1; of these, only 5 missense but no abrogating mutations
were found (97). Valdman et al. analyzed 21 prostate tumors
by Sanger sequencing and found no detectable BRG1 mutations
(113), whereas BRG1 expression is lost in 18–32% of prostate
tumors (Table 2A). Endo et al. analyzed 36 hepatocellular carci-
nomas, of which only four non-abrogating BRG1 mutations were
identified in two tumors (82). A combination of a loss of heterozy-
gosity and mutations is a frequent mechanism by which genes
are silenced in cancer, but despite the discovery of loss of het-
erozygosity at the BRG1 locus, Gunduz et al. did not identify any
mutations in BRG1 in primary oral cancers (78). Yet BRG1 is lost
in 18% of these tumors according to IHC data as illustrated in
Table 2A.
In each of these cases, BRG1 mutations occurred in a subset
of tumors, but these observed mutational rates cannot explain
why or how BRG1 is silenced, given the higher rate of BRG1
expression loss. Hence, other mechanisms are likely occurring
that silence BRG1. Whether silencing occurs by biallelic deletion
of BRG1, aberrant BRG1 splicing, microRNA regulation, some
other epigenetic mechanism or some combination of these mech-
anisms that has not yet been experimentally defined, is unknown.
Indeed, there is clear evidence that each of these mechanisms can
be involved in BRG1 silencing. As noted above, both BRM and
BRG1 loci have been reported to be sites of loss of heterozygos-
ity (76, 77, 79, 81). Given the frequent loss of one allele, it is
possible that the second allele could also be lost, which could
result in the silencing of these genes. In addition, microRNA
(specifically miR-21), which is elevated in a variety of tumors
and is functionally linked to cell growth and migration, has been
reported to regulate BRG1 (114). A number of BRG1-deficient
cell lines harbor aberrant BRG1 splicing defects where the BRG1
wild-type transcript is replaced by a transcript in which one
or more BRG1 exons are omitted, which typically results in a
frame-shifted protein. Epigenetic regulation of BRG1 akin to the
reported regulation of BRM has also been recently observed in
BRG1-deficient cell lines. Understanding the mechanisms that
drive BRG1 silencing in primary tumors could be used to delin-
eate which patients might benefit from BRG1-directed or other
targeted therapies.
ARID1A, ARID1B, ARID2, AND PBRM1 CAN BE FREQUENTLY MUTATED
IN SPECIFIC TUMOR TYPES
A series of NextGen sequencing studies have revealed that
other SWI/SNF subunits are targeted by mutations. These stud-
ies have shown that ARID1A (BAF250A), ARID1B (BAF250B),
PBRM1 (BAF180), and ARID2 (BAF200) have a weighted average
mutation rate of 4.83, 3.05, 1.69, and 4.24%, respectively, in 23
tumors from the publicly available TCGA database (Table 1). In
comparison, all the other SWI/SNF subunits have <2.4% weighted
mutation rate. ARID1A is mutated in 7.3% of stomach, 11.9% of
colon, 8.8% of pancreatic, 23.1% of cervical, 44.4% of endome-
trial, 18.1% of bladder, and 9.0% of adenocarcinoma lung cancers
(TCGA database) (Table 3A). In those tumors where ARID1A
is most frequently mutated, such as endometrial, bladder, pan-
creatic, and cervical cancers (66), more than ~60–80% of these
mutations are abrogating and likely cause the disruption of pro-
tein expression. Similarly, the homolog of ARID1A, ARID1B, is
frequently mutated in endometrial cancer (9.7%) and in hepato-
cellular carcinoma (10.4%) (Table 3B) (115), but the abrogation
mutation rate is <1%, which indicates that these are missense
(i.e., silent) mutations which do not effect ARID1B expression.
In contrast, the abrogating mutation rate of ARID1A is 36.3% in
endometrial cancer and 8.91% in hepatocellular cancer (Table 3A).
Likewise, the rate of abrogating mutations in PBRM1 is (21.1%)
[22.5%] out of a total mutation rate of (26.6%) [27.5%] in renal
cell carcinomas as indicated in the TCGA and Cosmic databases
(Table 4A). For published studies where N > 220 cases, the muta-
tional frequency for PBRM1 in renal cell carcinomas has been
reported to be 24, 38, and 41% by Kapur et al., Pena-Llopis et al.,
and Varela et al., respectively (116–118). In two of these studies,
the delineation of mutation types was not given so the impact
on expression could not be clarified. Nevertheless, the abrogat-
ing mutation rate can be estimated from the TCGA and Cosmic
databases, where abrogating mutations are found to be 75–80%
of the total mutations. Hence, applying this frequency of abro-
gating mutations indicates that the loss of PBRM1 occurs in
about 20–33% of renal cell tumors. In the study by Pena-Llopis
et al. (118), the abrogating mutational rate was 36%. In com-
parison, the loss of PBRM1 is between 53 and 70% from the
published IHC data (119), which suggests that mutations are not
the only mechanism underlying PBRM1 silencing in renal cell
carcinomas (119, 120).
Despite the apparent high frequency of ARID1A mutations
from the TCGA database in some primary tumors such as pancre-
atic (8.8%), stomach (7.3%), and endometrial (44.4%), BAF250
Table Notes
Abrogating, non-abrogating, and total mutation rates from the TCGA
and the Cosmic Databases for SMARCA4 (BRG1):Table 2A, SMARCA2
(BRM ): Table 2A, ARID1A (BAF250a): Table 3A, ARID1B (BAF250b):
Table 3B, PBRM1 (BAF180):Table 4A, and ARID2 (BAF200):Table 4B.
A total of 23 tumors are listed in the first column. The second column
lists the total number of tumors that were analyzed inTCGA database for
each tumor type. Next, the percentages of non-abrogating (Nabr), abro-
gating (Abr) mutations, and total (Nabr+Abr) mutation for each tumor
type are given. Similar data are then provided for the 13 tumors in the
Cosmic database.The penultimate column lists the range of percent loss
of SMARCA4 according to immunohistochemical studies, and the final
column provides the references for the IHC studies that were included.
The final row gives the unweighted average percentage of Nabr, Abr,
and total mutations for all 23 tumor types listed, forTCGA database and
the 13 tumors listed for Cosmic database.
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Table 2A | SMARCA4 (BRG1).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage IHC References
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%) Range (%)
Acute myeloid leukemia 197 0.00 0.00 0.00
Adrenocortical carcinoma 80 3.75 0.00 3.75
Bladder urothelial carcinoma 237 5.49 0.42 5.91 Bladder 5.66 0.00 5.66 11.9 (3)
Brain lower grade glioma 289 3.11 0.00 3.11 19.2 (102)
Breast invasive carcinoma 981 0.71 0.71 1.43 Breast 0.78 0.39 1.17 30–40 Marquez et al.
(submitted), (103)
Cervical cancer 39 2.56 0.00 2.56 22–40 Marquez et al.
(submitted), (104)
Colon adenocarcinoma 269 0.00 0.00 0.00 Colon 5.75 1.28 7.03 26–48
Endometrial cancer 248 9.68 0.00 9.68 Endometrium 9.61 0.36 9.96
Esophageal cancer 282 2.10 1.10 3.20 Esophageal 4.62 0.60 5.23 11.9 Marquez et al.
(submitted)
Glioblastoma multiforme 291 0.69 0.00 0.69 17–22 Marquez et al.
(submitted), (105)
Head/neck cancer 306 5.56 0.33 5.88 18.0
Kidney chromophobe 66 1.52 0.00 1.52
Kidney renal clear-cell
carcinoma
417 1.68 0.24 1.92 Kidney 1.05 0.00 1.05 70.0 Marquez et al.
(submitted)
Kidney renal papillary cell
carcinoma
112 5.36 0.00 5.36
Lung adenocarcinoma 544 6.07 3.31 9.38 Lung 4.21 3.06 7.27 16–37 Marquez et al.
(submitted), (19,
101, 106)
Lung squamous cell
carcinoma
178 3.93 0.56 4.49 22–27 Marquez et al.
(submitted), (5)
Ovarian carcinoma (serous) 230 1.74 0.00 1.74 Ovarian 1.61 0.00 1.61 18.7 Marquez et al.
(submitted)
Serous 1.20 0.10 1.30
Clear cell 9.10 0.00 9.10
Pancreatic adenocarcinoma 57 6.59 1.10 7.69 Pancreatic 1.00 1.00 1.99 12–25 Marquez et al.
(submitted), (98)
Prostate adenocarcinoma 251 0.00 0.00 0.00 Prostate 0.0 0.6 0.0 18–32 Marquez et al.
(submitted), (106,
107)
Rectum adenocarcinoma 116 3.45 0.00 3.45
Skin cutaneous melanoma 345 7.54 0.29 7.83 Melanoma 7.55 0.63 8.18 10–27 Marquez et al.
(submitted), (100)
Stomach adenocarcinoma 245 3.27 0.82 4.08 Stomach 1.54 0.00 1.54 0–3 Marquez et al.
(submitted), (108)
Thyroid carcinoma 405 0.99 0.00 0.99 7.9 Marquez et al.
(submitted)
Uterine carcinosarcoma 114 0.88 0.88 1.75
Hepatocellular carcinoma 202 6.44 0.99 7.43 Liver 1.63 0.61 2.24 40–60 Marquez et al.
(submitted), (82)
Unweighted average 3.32 0.43 3.75 3.69 0.58 4.22
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Table 2B | SMARCA2 (BRM).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage IHC References
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%) Range (%)
Acute myeloid leukemia 197 1.02 0.00 1.02
Adrenocortical carcinoma 80 1.25 0.00 1.25
Bladder urothelial carcinoma 237 4.64 0.00 4.64 Bladder 5.83 0.00 5.83 15.20 (3)
Brain lower grade glioma 289 0.00 0.00 0.00
Breast invasive carcinoma 981 1.02 0.31 1.33 Breast 0.64 0.00 0.64 14.90 (3)
Cervical cancer 39 0.00 0.00 0.00
Colon adenocarcinoma 269 0.00 0.00 0.00 Colon 1.31 0.16 1.48 70 (105)
Endometrial cancer 248 10.48 0.00 10.48 Endometrium 8.54 0.03 8.57
Esophageal cancer 282 2 0 2.1 Esophageal 5.20 0.58 5.78 9 (3)
Glioblastoma multiforme 291 1.03 0.00 1.03
Head/neck cancer 306 2.61 0.65 3.27 16 (63)
Kidney chromophobe 66 4.55 0.00 4.55
Kidney renal clear-cell
carcinoma
417 0.48 0.24 0.72 Kidney 0.88 0.00 0.88 53 Marquez
et al.
(submitted)
Kidney renal papillary cell
carcinoma
112 0.89 0.89 1.79
Lung adenocarcinoma 544 4.60 0.00 4.60 Lung 3.73 0.12 3.85 30–39 (3, 19, 101)
Lung squamous cell
carcinoma
178 3.37 0.00 3.37 21–32 (3, 5)
Ovarian carcinoma (serous) 230 0.00 0.00 0.00 Ovarian (serous) 0.80 0.00 0.80 17–7 (3)
Clear cell 0.00 0.00 0.00
Endometrioid 0.00 0.00 0.00
Pancreatic adenocarcinoma 57 3.30 0.00 3.30 Pancreatic 1.23 0.01 1.23 50 (100)
Prostate adenocarcinoma 251 0.00 0.40 0.40 Prostate 1.00 0.00 1.00 35–47 (109, 110)
Rectum adenocarcinoma 116 2.59 0.00 2.59
Skin cutaneous melanoma 345 4.64 0.00 4.64 Melanoma 1.25 0.00 1.26 20 (111)
Stomach adenocarcinoma 245 2.45 0.00 2.45 Stomach 0.00 0.00 0.00 42 (108)
Thyroid carcinoma 405 0.25 0.00 0.25
Uterine carcinosarcoma 114 2.63 0.00 2.63
Hepatocellular carcinoma 202 12.87 0.00 12.87 Liver 1.93 0.24 2.18 22.50 (82)
Unweighted average 10.59 0.10 11.09 2.16 0.08 2.23
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Table 3A | ARID1A (BAF250a).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage IHC References
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%) Range (%)
Acute myeloid leukemia 197 0.5 0.0 0.5
Adrenocortical carcinoma 80 0.0 1.3 1.3
Bladder urothelial carcinoma 237 5.9 12.2 18.1 Bladder 6.1 14.0 20.1 ~34 (121)
Brain lower grade glioma 289 0.3 4.8 5.2
Breast invasive carcinoma 981 1.2 2.0 3.3 Breast 1.8 1.7 3.5 60–65 (122–124)
Cervical cancer 39 5.1 17.9 23.1 6–20 (125, 126)
Colon adenocarcinoma 269 4.1 7.8 11.9 Colon 9.4 7.0 16.4 4–8 (127, 128)
Endometrial cancer 248 8.1 36.3 44.4 Endometrium 9.3 34.9 44.1 15–34 (129–131)
Esophageal cancer 282 2.80 3.50 6.40 Esophageal 3.5 13.3 16.8
Glioblastoma multiforme 291 1.4 0.0 1.4
Head/neck cancer 306 4.9 2.3 7.2 0.0 (128, 132)
Kidney chromophobe 66 0.0 0.0 0.0
Kidney renal clear-cell
carcinoma
417 1.0 0.5 1.4 Kidney 0.6 0.3 0.9 0–2 (128, 132, 133)
Kidney renal papillary cell
carcinoma
112 4.5 0.0 4.5
Lung adenocarcinoma 544 4.2 4.8 9.0 Lung 4.7 2.3 7.1 2.1–7.4 (128, 132)
Lung squamous cell
carcinoma
178 6.2 2.8 9.0 10 (128)
Ovarian carcinoma (serous) 230 0.0 0.0 0.0 Ovarian 0.6 8.6 9.2 45–60 (134–140)
Endometrioid 2.6 44.7 47.4 48–83 (135, 136, 138)
Serous 0.1 1.0 1.1 60.0 (138)
Clear-cell 1.7 60.9 62.6 41–75 (134–140)
Pancreatic adenocarcinoma 57 3.3 5.5 8.8 Pancreatic 1.5 5.7 7.2 6–8.5 (132)
Prostate adenocarcinoma 251 1.6 0.0 1.6 Prostate 1.2 0.3 1.6 0–5 (127, 128)
Rectum adenocarcinoma 116 1.7 2.6 4.3 1.0 (132)
Skin cutaneous melanoma 345 6.1 1.7 7.8 Melanoma 4.3 1.5 5.8
Stomach adenocarcinoma 245 4.9 2.4 7.3 Stomach 4.2 12.6 16.7 14–25 (132, 141–143)
Thyroid carcinoma 405 0.0 0.0 0.0 10–14 Marquez et al.
(submitted),
(132)
Uterine carcinosarcoma 114 2.6 3.5 6.1 14.0 (132, 144)
Hepatocellular carcinoma 202 5.94 8.91 14.85 Liver 3.9 10.2 14.1
Unweighted average 3.05 4.84 7.90 3.47 13.69 17.16
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Table 3B | ARID1B (BAF250b).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%)
Acute myeloid leukemia 197 0.0 0.0 0.0
Adrenocortical carcinoma 80 0.0 1.3 1.3
Bladder urothelial carcinoma 237 1.3 2.1 3.4 Bladder 2.9 1.9 4.9
Brain lower grade glioma 289 0.7 1.4 2.1
Breast invasive carcinoma 981 1.3 0.4 1.7 Breast 1.1 0.2 1.3
Cervical cancer 39 2.6 0.0 2.6
Colon adenocarcinoma 269 5.6 0.7 6.3 Colon 4.6 0.9 5.5
Endometrial cancer 248 9.7 0.0 9.7 Endometrium 7.3 1.7 9.0
Esophageal cancer 282 2.50 0.70 3.20 Esophageal 1.2 0.6 1.7
Glioblastoma multiforme 291 1.0 0.0 1.0
Head/neck cancer 306 5.9 0.7 6.5
Kidney chromophobe 66 0.0 0.0 0.0
Kidney renal clear-cell carcinoma 417 1.0 0.2 1.2 Kidney 1.7 0.0 1.7
Kidney renal papillary cell
carcinoma
112 2.7 0.0 2.7
Lung adenocarcinoma 544 5.0 0.6 5.5 Lung 4.3 0.6 4.9
Lung squamous cell carcinoma 178 6.2 0.6 6.7
Ovarian carcinoma (serous) 230 0.0 0.0 0.0 Ovarian 0.2 0.4 0.6
Serous 0.2 0.2 0.4
Clear cell 0.0 12.5 12.5
Pancreatic adenocarcinoma 57 4.4 0.0 4.4 Pancreatic 1.2 0.1 1.3
Prostate adenocarcinoma 251 2.4 0.4 2.8 Prostate 1.3 0.3 1.6
Rectum adenocarcinoma 116 2.6 0.0 2.6
Skin cutaneous melanoma 345 5.5 2.0 7.5 Melanoma 0.6 0.0 0.6
Stomach adenocarcinoma 245 4.5 0.4 4.9 Stomach 2.1 4.3 6.4
Thyroid carcinoma 405 0.2 0.2 0.5
Uterine carcinosarcoma 114 0.9 0.0 0.9
Hepatocellular carcinoma 202 9.41 0.99 10.40 Liver 1.7 0.2 1.9
Unweighted average 3.01 0.51 3.51 2.02 1.59 3.62
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Table 4A | PRBM1 (BAF180).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage IHC Reference
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%) Range (%)
Acute myeloid leukemia 197 0.00 0.00 0.00
Adrenocortical carcinoma 80 1.25 0.00 1.25
Bladder urothelial carcinoma 237 4.22 0.84 5.06 Bladder 5.8 0.0 5.8
Brain lower grade glioma 289 1.38 1.04 2.42
Breast invasive carcinoma 981 0.71 0.20 0.92 Breast 0.4 0.4 0.8
Cervical cancer 39 5.13 0.00 5.13
Colon adenocarcinoma 269 0.00 0.00 0.00 Colon 1.0 0.3 1.3
Endometrial cancer 248 3.23 1.61 4.84 Endometrium 3.7 1.7 5.3
Esophageal cancer 282 1.40 0.00 1.40 Esophageal 0.0 2.3 2.3
Glioblastoma multiforme 291 0.69 0.00 0.69
Head/neck cancer 306 2.29 1.31 3.59
Kidney chromophobe 66 0.00 0.00 0.00
Kidney renal clear-cell carcinoma 417 5.52 21.10 26.62 Kidney 5.0 22.5 27.5 54–68 (119)
Kidney renal papillary cell
carcinoma
112 0.89 2.68 3.57
Lung adenocarcinoma 544 1.65 0.55 2.21 Lung 2.2 0.5 2.6
Lung squamous cell carcinoma 178 3.93 0.00 3.93
Ovarian carcinoma (serous) 230 0.00 0.00 0.00 Ovarian (serous) 0.0 0.2 0.2
Clear cell 0.0 0.0 0.0
Endometrioid 0.0 0.0 0.0
Pancreatic adenocarcinoma 57 2.20 1.10 3.30 Pancreatic 0.3 0.7 1.0
Prostate adenocarcinoma 251 0.00 0.00 0.00 Prostate 0.0 0.0 0.0
Rectum adenocarcinoma 116 3.45 0.86 4.31
Skin cutaneous melanoma 345 3.19 2.61 5.80 Melanoma 0.6 0.0 0.6
Stomach adenocarcinoma 245 2.86 0.82 3.67 Stomach 3.1 0.0 3.1
Thyroid carcinoma 405 0.00 0.00 0.00
Uterine carcinosarcoma 114 0.88 0.00 0.88
Hepatocellular carcinoma 202 4.95 0.99 5.94 Liver 1.9 0.5 2.4
Unweighted average 1.99 1.43 3.42 1.60 1.93 3.53
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Table 4B | ARID2 (BAF200).
Mutations Tumor TCGA: percentage Tumor Cosmic: percentage
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%)
Acute myeloid leukemia 197 0.0 0.5 0.5
Adrenocortical carcinoma 80 0.0 0.0 0.0
Bladder urothelial carcinoma 237 3.8 1.3 5.1 Bladder 3.9 0.0 3.9
Brain lower grade glioma 289 0.7 0.7 1.4
Breast invasive carcinoma 981 1.1 0.3 1.4 Breast 0.6 0.5 1.2
Cervical cancer 39 2.6 0.0 2.6
Colon adenocarcinoma 269 3.7 3.0 6.7 Colon 7.4 3.2 10.5
Endometrial cancer 248 8.1 2.4 10.5 Endometrium 8.9 1.8 10.7
Esophageal cancer 282 1.10 1.10 2.10 Esophageal 2.3 1.7 4.1
Glioblastoma multiforme 291 0.3 0.3 0.7
Head/neck cancer 306 2.0 3.3 5.2
Kidney chromophobe 66 0.0 0.0 0.0
Kidney renal clear- cell carcinoma 417 0.5 0.2 0.7 Kidney 0.6 0.2 0.8
Kidney renal papillary cell
carcinoma
112 0.9 0.9 1.8
Lung adenocarcinoma 544 3.9 4.6 8.5 Lung 3.7 2.2 5.9
Lung squamous cell carcinoma 178 8.4 0.6 9.0
Ovarian carcinoma (serous) 230 0.4 0.0 0.4 Ovarian (serous) 1.3 0.0 1.3
Clear cell 0.0 0.0 0.0
Endometroid 0.0 0.0 0.0
Pancreatic adenocarcinoma 57 4.4 0.0 4.4 Pancreatic 3.3 1.7 5.0
Prostate adenocarcinoma 251 0.8 1.2 2.0 Prostate 0.6 0.0 0.6
Rectum adenocarcinoma 116 5.2 1.7 6.9
Skin cutaneous melanoma 345 9.6 8.4 18.0 Melanoma 4.1 6.1 10.2
Stomach adenocarcinoma 245 6.1 0.4 6.5 Stomach 3.1 0.0 3.1
Thyroid carcinoma 405 0.0 0.5 0.5
Uterine carcinosarcoma 114 0.0 0.0 0.0
Hepatocellular carcinoma 202 4.5 3.5 7.9 Liver 2.8 6.7 9.5
Unweighted average 2.72 1.39 4.11 2.85 1.61 4.46
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was initially noted to be infrequently silenced in cancer cell lines
(96). ARID2 was discovered by Weidong Wang in 2000 and
found to be infrequently lost in cancer cell lines (145) but was
recently reported to be mutated in 18% of melanoma and 7.9% of
HCV-associated hepatocellular carcinomas (146–148). The TCGA
database further shows that ARID2 is also frequently mutated in
(10.5%) of endometrial cancers (2.6%) of cervical cancers, and
(5.1%) of bladder cancers (Table 4B). Similarly PBRM1was found
to be infrequently silenced by mutations in human cancer cell lines
(96); in contrast, PBRM1 has been found to be silenced in 3.6–7%
of stomach, endometrial, melanoma, pancreatic, cervical, bladder,
and head/neck cancers based on the TCGA database. In compari-
son, PBRM1 is 3.8–7.4 times more frequently mutated in (26.62%)
[27.5%] renal cell carcinomas than in these other tumor types.
To determine the role of mutations in the silencing of a given
gene, one must compare the mutation rates and loss of expres-
sion data (IHC) for that gene. It should be noted that the validity
of such an analysis is dependent on the accuracy of the reported
mutational rates, which can vary depending on the study or data-
base used. For this reason, we have chosen to standardize our
comparison using the TCGA database. To this end, IHC data are
primarily only available for ARID1A, BRG1, and BRM. The loss of
ARID1A expression as determined by IHC and predicted by abro-
gating mutation rates as designated by “(%)” is illustrated in the
following tumor types: ~14–25% (2.4%) of gastric cancers (141),
15–34% (36.3%) of endometrial carcinomas (129, 132, 149), 0–2%
(0.5%) of renal cell cancers (121, 133), 60–65% (2.0%) of breast
cancers (122–124, 150, 151), and 10% (2.8%) of squamous cell
lung cancers (128). Hence, mutations do appear to account for the
loss of ARID1A in certain tumor types, as the abrogating muta-
tion rates are comparable to the loss of expression for endometrial
tumors as determined by IHC. In other tumor types, however,
the reported abrogating mutation rates are less than the frequency
of gene expression. For example, nearly 60% of breast cancers
demonstrate low to no ARID1A expression (123, 150), while 2.0%
[1.7%] of breast cancers showed ARID1A mutations. Nearly 80%
of these breast tumors demonstrated promoter methylation (122),
and the heterozygous and homozygous allelic loss of ARID1A
occurred in 35.2 and 2% of cases, respectively, in breast cancer
(151). These data again show that mutations do occur in ARID1A
and likely account for the loss of ARID1A expression in some
tumor types, but that in other tumor types, other mechanisms
of gene silencing must underlie ARID1A silencing. In addition,
when mutations are detected in tumors, it does not necessarily
mean that they are ubiquitously distributed in every tumor cell.
As immunohistochemical studies accumulate, the mechanism of
the silencing/abrogation of the other SWI/SNF subunits will be
able to be evaluated.
BRM silencing is unlike BRG1 silencing; with respect to BRM,
mutations are rarely if ever documented in cancer cell lines (3). In
fact, in the majority of BRM-deficient cell lines (20/20), BRM can
be readily induced by a variety of agents (50). NextGen sequenc-
ing of BRM in numerous tumor types has substantiated this initial
observation. The abrogating mutation and total mutation rate for
BRM is (<1%) [<1%] and (<11.1%) [<2.6%], respectively, for
each of the 23 tumor types available in the TCGA database and the
13 tumor types compiled from the Cosmic database (Table 2B). In
comparison, the NextGen sequencing analysis of genetic disorders
has revealed BRM germline mutations are higher in some genetic
disorders than in cancer. For example, analysis of individuals with
Nicolaides–Baraitser syndrome, a rare disease distinguished by
sparse hair, unique facial morphology, distal limb abnormalities,
and intellectual disability, showed that SMARCA2 (BRM) har-
bored missense mutations in 36 of 44 cases (~80%). Moreover,
these mutations were harbored within conserved catalytic ATPase
regions, suggesting that mutations do cluster within hotspots in
certain diseases. Similarly, in another study, SMARCA2 (BRM)
was mutated in 43% of patients with Coffin–Siris syndrome. Muta-
tions in Coffin–Siris also occur in SMARCB1 (BAF47), SMARCA4
(BRG1), SMARCE1, ARID1A, and ARID1B, which attests to the
role of the SWI/SNF complex in this genetic disorder.
GENOMIC NEXTGEN SEQUENCING VERSUS mRNA SPLICING
Alternative splicing is a frequent mechanism that leads to aberrant
or a complete loss of gene expression. As NextGen sequencing
detects deviations in genomic DNA sequences within the coding
regions of genes, splicing defects that occur by other mechanisms
that do not involve the splicing junctions, but rather in acceptor
or donor sites, may not be detected. Genomic DNA changes that
affect the composition of branchpoint sequences or their relative
position from the 3′ splice acceptor site of the downstream exon
are also known to impact splicing, and certain missense muta-
tions might be sufficient to create cryptic sites within the coding
region. While non-mutational mechanisms can be inferred when
the mutation rates do not match the frequency of gene silenc-
ing, other abrogating mechanisms such as aberrant splicing could
contribute to this observed difference. Testing in cell lines permits
the resolution of this type of discrepancy, but analyses in tumors
are much more complicated because tumors are heterogeneous
and multiple mechanisms may be active in a single tumor. More-
over, the mRNA levels that result from aberrant splicing are much
lower than the mRNA level derived from the normal tissue within
most tumor samples; this fact further complicates the detection
and analysis of aberrant splicing in tumors compared with cell
lines that lack these constraints. Hence, the notion that mutations
and non-mutational mechanisms must be mutually exclusive is
not true. It is more likely that both mechanisms are operating
independently of each other and that the prevalence of each mech-
anism is driven by the selection force confronted by the tumor in
its environment.
RHABDOID TUMORS, MUTATIONS AND THE SWI/SNF
COMPLEX
SMARCB1 (INI1 or BAF47 ) was the first gene of the SWI/SNF
complex that was linked to cancer. The discovery of the role of
this gene in the genesis of malignant Rhabdoid pediatric sarcomas
was interesting. Mouse models have shown that the inactivation of
the BAF47 gene is highly tumorigenic. One might have thought,
therefore, that this gene would be targeted and activated in a
wide range of other cancer types, given its apparent degree of
tumorigenicity. However, this is not the case, as the Atlas data-
base shows that mutations in SMARCB1 are relatively infrequent;
the average weighted abrogating and total mutation rate is only
0.13% and 0.66%, respectively, in the TCGA database (Table 1).
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Several other SWI/SNF subunits are also infrequently mutated:
SMARCD1, SMARCD2, SMARCD3, and SMARCE1 have average
weighted mutation rates of 0.27, 0.64, 0.88, and 0.40%, respec-
tively, in the TCGA database. These subunits, like SMARCB1, are
smaller subunits within the SWI/SNF complex (i.e., the molecu-
lar weight of each is under 60 kDa). In comparison, the weighted
mutation rates of the large subunits that are in the 180–250 kDa
range are generally higher than those of the small subunits, which
suggests that this observed difference in the mutation rates may
in part be due to the size differences of the subunits. If the
mutation rate for each subunit is adjusted for the size differ-
ence by dividing the weighted mutation rates by the length/size
in 100 kDa, then the size-adjusted-mutation rates for SMARCD1,
SMARCD2, SMARCD3, and SMARCE1 become (mutation per-
centage/100 kDa): 0.43, 1.01, 1.42, and 0.69%, respectively. In
comparison, the mutation percentages per 100 kDa for BRG1,
BRM, ARID1A, ARID1B, ARID2, and PBRM1 are 1.27, 1.03, 1.93,
1.22, 2.12, and 0.93%, respectively. When corrected for size, most
SWI/SNF subunits harbor 1% (±0.4%) mutations per 100 kDa,
while the standardized mutational rates of ARID1A and ARID2
are about twice this rate. In most tumors, the mutation rate of
SMARCB1 is<1.0%. In cervical carcinomas, squamous cell carci-
nomas, and adenocarcinomas of the lung, however, the mutation
rates are 5.10, 1.7, and 2.8%, respectively (Table S1 in Supplemen-
tary Material). Most of these mutations do not affect the expression
of SMARCB1 as they are silent or missense mutations. For lung and
cervical cancers, the rate of abrogating mutations is 0.6 and 0.0%,
respectively. Thus, <1:200 of these tumors harbor a mutation in a
SMARCB1 allele.
ABROGATION OF SMARCB1 IN RHABDOID TUMORS LED TO
THE DISCOVERY OF SWI/SNF INVOLVEMENT IN CANCER
In 1990s, SMARCB1 mutations and the subsequent inactivation
of SMARCB1 in rhabdoid tumors led to the realization that the
SWI/SNF complex is often a target in cancer. Analyses of the vari-
ous subunits were pursued based on these facts, and it was assumed
that the SWI/SNF complex requires each of its subunits in order
to be functional. Therefore, it was surmised by Bernard Weissman
and others that the other SWI/SNF subunits must be involved in
cancer akin to the SMARCB1 gene (96). This premise led to the
finding that BRG1 and BRM are frequently silenced either alone
or concomitantly in lung cancer (6). However, a recent analysis of
rhabdoids has shown that BRG1 and BRM are also lost in many
Rhabdoid tumors (52). BRM is silenced in 60–70% of primary
rhabdoid tumors and in >90% of rhabdoid cell lines (52). Inter-
estingly, the mechanism of silencing of BRM in rhabdoid tumors
appears to be identical to that reported in lung cancer (52). Hence,
BRM silencing appears to be conserved between these two very
different cancer types. Similarly, BRG1 is silenced in about 50% of
primary rhabdoid tumors and about 75% of rhabdoid cell lines
(unpublished data). In BRM-deficient rhabdoid cell lines and in a
subset of BRG1-deficient rhabdoid cell lines, each of these genes is
epigenetically silenced, and their expression can be restored (52).
Remarkably, both genes can be readily restored by flavopiridol in
a subset of lung and rhabdoid BRG1/BRM-deficient cancer cell
lines (50, 52). As BRG1 and BRM complement the function of RB
and RB2 in growth inhibition, their induction could be a necessary
prerequisite for the clinical activity of flavopiridol. The epigenetic
silencing of BRM and BRG1 is in concert with the fact that there
are few mutated genes in rhabdoid tumors. Hence, the study of the
epigenetic mechanism behind BRM and BRG1 silencing in rhab-
doid tumors and potentially in other tumor types would seem to
be important and a novel avenue for cancer research.
IN SUMMARY
In recent reviews of the role of SWI/SNF in cancer, the majority of
mutations discussed are missense and not abrogating mutations,
yet overwhelming data show that SWI/SNF can be inactivated
by both mutations and non-mutational silencing. These findings
demonstrate that SWI/SNF function must be negatively impacted
even more frequently than suggested by Kadoch et al. (65). The
exact frequency of SWI/SNF impairment cannot yet be estimated
from mutational analyses alone, but based on currently available
data, SWI/SNF is impaired in at least 16% via mutations – and
possibly >90% – of cancers, if one considers all mechanisms of
inactivation.
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